Monday, April 27, 2015 11:18:42 AM
TMM, Inc. (TMMI-PK) (“TMMI”) or (the “Company”) is pleased to announce that the Inter Partes Review (“IPR”) Petition that TMMI filed with the USPTO Patent Trial and Appeal Board (“Board”) in May 2014 seeking to invalidate the operative claims of Dimension, Inc.’s Patent Number 8,639,053 has resulted in the Board’s issuance of a final adverse judgment order against Dimension (the patent owner) cancelling each of the 25 operative ‘053 patent claims (1-16, 22-30) of Dimension.
Trial was not instituted by the Board on the 5 dependent claims (17-21) which are unrelated to TMM’s proprietary technology and are considered by TMMI to be so narrow that they do not in any way apply to or limit such proprietary technology. As a result, TMMI contemplates no further action with respect to such inoperative claims at this time even though they are also deemed invalid on their face on the basis of multiple instances of prior art.
TMMI will continue to aggressively protect TMMI’s proprietary intellectual property and related assets as necessary.
ON BEHALF OF THE TMMI BOARD OF DIRECTORS OF TMM, INC.:
GERARD V. CAVANAUGH
CHAIRMAN AND PRESIDENT
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM